Literature DB >> 25059457

Correlations between plasma levels of amino acids and nonmotor symptoms in Parkinson's disease.

Qing Tong1, Qinrong Xu, Qiang Xia, Yongsheng Yuan, Li Zhang, Hongbin Sun, Han Shan, Kezhong Zhang.   

Abstract

Converging evidence suggests that changes in plasma levels of amino acids are involved in Parkinson's disease (PD), but their roles in nonmotor symptoms (NMS) of PD remain unclear. The aim of this study was to evaluate the correlations between plasma amino acids and NMS of PD. Plasma levels of aspartate (Asp), glutamate (Glu), glycine (Gly) and γ-aminobutyric acid (GABA) were measured in 92 PD patients and 60 healthy controls. Four NMS, including depression, pain, sleep disturbances and autonomic dysfunction were assessed in enrolled subjects using the Hamilton Depression Scale, the short form of the McGill Pain Questionnaire, the Pittsburgh Sleep Quality Index and the Scale for Outcomes in Parkinson's disease for Autonomic Symptoms, respectively. Hierarchical multiple regression analysis was used to evaluate the correlations between plasma levels of amino acids and NMS. PD patients exhibited significantly higher scores of NMS scales and lower plasma levels of amino acids compared to healthy controls. Within the PD group, plasma levels of Asp and Glu were negatively associated with the severity of depression and sleep disturbances. Moreover, decreased plasma level of GABA was correlated with more severe symptoms of sleep disturbances. After controlling for gender, disease duration, severity of motor symptoms and anti-parkinsonian medications, Glu but not Asp remained significantly associated with depression, along with Asp, GABA but not Glu remained negatively associated with sleep disturbances. The altered plasma levels of amino acids may be implicated in the pathogenesis of NMS of PD.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25059457     DOI: 10.1007/s00702-014-1280-5

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  36 in total

1.  Neurotransmitter amino acids in cerebrospinal fluid of patients with Parkinson's disease.

Authors:  F J Jiménez-Jiménez; J A Molina; C Vargas; P Gómez; J A Navarro; J Benito-León; M Ortí-Pareja; T Gasalla; E Cisneros; J Arenas
Journal:  J Neurol Sci       Date:  1996-09-15       Impact factor: 3.181

2.  Force overflow and levodopa-induced dyskinesias in Parkinson's disease.

Authors:  Roland Wenzelburger; Bao-Rong Zhang; Sabine Pohle; Stephan Klebe; Delia Lorenz; Jan Herzog; Henrik Wilms; Günther Deuschl; Paul Krack
Journal:  Brain       Date:  2002-04       Impact factor: 13.501

3.  Correlation of findings in advanced MRI techniques with global severity scales in patients with Parkinson disease.

Authors:  Pedro J Modrego; Nicolás Fayed; Jorge Artal; Salvador Olmos
Journal:  Acad Radiol       Date:  2011-02       Impact factor: 3.173

4.  A significant reduction of putative transmitter amino acids in cerebrospinal fluid of patients with Parkinson's disease and spinocerebellar degeneration.

Authors:  H Tohgi; T Abe; K Hashiguchi; S Takahashi; Y Nozaki; T Kikuchi
Journal:  Neurosci Lett       Date:  1991-05-27       Impact factor: 3.046

5.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.

Authors:  A J Hughes; S E Daniel; L Kilford; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-03       Impact factor: 10.154

Review 6.  The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the non-motor symptoms of Parkinson's disease.

Authors:  Klaus Seppi; Daniel Weintraub; Miguel Coelho; Santiago Perez-Lloret; Susan H Fox; Regina Katzenschlager; Eva-Maria Hametner; Werner Poewe; Olivier Rascol; Christopher G Goetz; Cristina Sampaio
Journal:  Mov Disord       Date:  2011-10       Impact factor: 10.338

7.  Amino acids in plasma and CSF and monoamine metabolites in CSF: interrelationship in healthy subjects.

Authors:  L Hagenfeldt; L Bjerkenstedt; G Edman; G Sedvall; F A Wiesel
Journal:  J Neurochem       Date:  1984-03       Impact factor: 5.372

8.  Ventricular cerebrospinal fluid concentrations of putative amino acid transmitters in Parkinson's disease and other disorders.

Authors:  H Perschak; U Amsler; A Vischer; J Siegfried; M Cuénod
Journal:  Hum Neurobiol       Date:  1987

9.  Elevated pontine and putamenal GABA levels in mild-moderate Parkinson disease detected by 7 tesla proton MRS.

Authors:  Uzay E Emir; Paul J Tuite; Gülin Öz
Journal:  PLoS One       Date:  2012-01-25       Impact factor: 3.240

10.  Plasma amino acids changes in complex regional pain syndrome.

Authors:  Guillermo M Alexander; Erin Reichenberger; B Lee Peterlin; Marielle J Perreault; John R Grothusen; Robert J Schwartzman
Journal:  Pain Res Treat       Date:  2013-11-04
View more
  8 in total

1.  Atp13a2 expression in the periaqueductal gray is decreased in the Pink1 -/- rat model of Parkinson disease.

Authors:  Cynthia A Kelm-Nelson; Sharon A Stevenson; Michelle R Ciucci
Journal:  Neurosci Lett       Date:  2016-04-04       Impact factor: 3.046

2.  L-DOPA Reverses the Increased Free Amino Acids Tissue Levels Induced by Dopamine Depletion and Rises GABA and Tyrosine in the Striatum.

Authors:  Oscar Solís; Patricia García-Sanz; Antonio S Herranz; María-José Asensio; Rosario Moratalla
Journal:  Neurotox Res       Date:  2016-03-10       Impact factor: 3.911

3.  Plasma Amino Acid Concentrations in Patients with Alcohol and/or Cocaine Use Disorders and Their Association with Psychiatric Comorbidity and Sex.

Authors:  Nuria García-Marchena; Alberto Marcos; María Flores-López; Mario Moreno-Fernández; Nerea Requena-Ocaña; Oscar Porras-Perales; Sandra Torres-Galván; Pedro Araos; Antonia Serrano; Roberto Muga; Juan Jesús Ruiz-Ruiz; Fernando Rodríguez de Fonseca; Emilio Ambrosio; Francisco Javier Pavón-Morón
Journal:  Biomedicines       Date:  2022-05-14

4.  Sodium p-Aminosalicylic Acid Reverses Sub-Chronic Manganese-Induced Impairments of Spatial Learning and Memory Abilities in Rats, but Fails to Restore γ-Aminobutyric Acid Levels.

Authors:  Shao-Jun Li; Chao-Yan Ou; Sheng-Nan He; Xiao-Wei Huang; Hai-Lan Luo; Hao-Yang Meng; Guo-Dong Lu; Yue-Ming Jiang; Tanara Vieira Peres; Yi-Ni Luo; Xiang-Fa Deng
Journal:  Int J Environ Res Public Health       Date:  2017-04-10       Impact factor: 3.390

5.  Reduced expression of somatostatin in GABAergic interneurons derived from induced pluripotent stem cells of patients with parkin mutations.

Authors:  Chizuru Iwasawa; Naoko Kuzumaki; Yukari Suda; Reiko Kagawa; Yuko Oka; Nobutaka Hattori; Hideyuki Okano; Minoru Narita
Journal:  Mol Brain       Date:  2019-01-18       Impact factor: 4.041

6.  Comparative study of striatum GABA concentrations and magnetic resonance spectroscopic imaging in Parkinson's disease monkeys.

Authors:  Lixuan Huang; Yande Ren; Zisan Zeng; Hao Ren; Shaojun Li; Shengnan He; Fan He; Xiangrong Li
Journal:  BMC Neurosci       Date:  2019-08-08       Impact factor: 3.288

7.  Bilateral Parkinson's disease model rats exhibit hyperalgesia to subcutaneous formalin administration into the vibrissa pad.

Authors:  Hiroharu Maegawa; Nayuka Adachi; Hiroshi Hanamoto; Chiho Kudo; Hitoshi Niwa
Journal:  PLoS One       Date:  2019-12-05       Impact factor: 3.240

8.  Genetically predicted circulating levels of glycine, glutamate, and serotonin in relation to the risks of three major neurodegenerative diseases: A Mendelian randomization analysis.

Authors:  Ruizhuo Li; Mengjuan Deng; Yuhong Lin; Wenjing Gao; Bohao Liu; Huimin Xia
Journal:  Front Aging Neurosci       Date:  2022-09-07       Impact factor: 5.702

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.